Clinical Neurology and Neurosurgery
Volume 112, Issue 7 , Pages 592-596 , September 2010

The place of the botulinum toxin in the management of multiple sclerosis

  • Mario Habek

      Affiliations

    • University of Zagreb, School of Medicine, Department of Neurology, Zagreb, Croatia
    • University Hospital Center Zagreb, Department of Neurology and Refferal Center for Demyelinating Diseases of the Central Nervous System, Zagreb, Croatia
    • Corresponding Author InformationCorresponding author at: University Department of Neurology, Zagreb School of Medicine and University Hospital Center, Kišpatićeva 12, HR-10000 Zagreb, Croatia. Tel.: +385 98883323; fax: +385 12421891.
    • ,
  • Arnon Karni

      Affiliations

    • Neuroimmunology Clinic, Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • Sackler School of Medicine, Tel-Aviv University, Israel
    • ,
  • Yakov Balash

      Affiliations

    • Movement Disorders Unit, Department of Neurology, Tel-Aviv Sourasky Medical Center, Israel
    • Sackler School of Medicine, Tel-Aviv University, Israel
    • ,
  • Tanya Gurevich

      Affiliations

    • Movement Disorders Unit, Department of Neurology, Tel-Aviv Sourasky Medical Center, Israel
    • Sackler School of Medicine, Tel-Aviv University, Israel

Received 28 March 2010 ,Accepted 6 April 2010.

References 

  1. Henze T. Managing specific symptoms in people with multiple sclerosis. Int MS J. 2005;12:60–68
  2. Lance JW. Symposium synopsis. In:  Feldman RG,  Young RR,  Koella WP editor. Spasticity: disordered motor control Chicago. Year Book Medical Publishers; 1980;
  3. Gormley ME, O’Brien CF, Yablon SA. A clinical overview of treatment decisions in the management of spasticity. Muscle Nerve Suppl. 1997;6:S14–20
  4. Bussel B, Neris OR, Mailhan L. Spasticity and multiple sclerosis. Rev Neurol (Paris). 2001;157:1041–1044
  5. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003;(4):CD001332
  6. Kabus C, Hecht M, Japp G, Jost WH, Pöhlau D, Stuckrad-Barre S, et al. Botulinum toxin in patients with multiple sclerosis. J Neurol. 2006;253(Suppl. 1):I26–I28
  7. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990;28:512–515
  8. Borg-Stein J, Pine ZM, Miller JR, Brin MF. Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations. Am J Phys Med Rehabil. 1993;72:364–368
  9. Finsterer J, Fuchs I, Mamoli B. Automatic EMG-guided botulinum toxin treatment of spasticity. Clin Neuropharmacol. 1997;20:195–203
  10. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68:707–712
  11. Sobolewski P. The application of botulinum toxin type A in the treatment of spastic paraparesis. Przegl Lek. 2007;64(Suppl. 2):3–7
  12. Restivo DA, Tinazzi M, Patti F, Palmeri A, Maimone D. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2003;61:719–720
  13. Pappert EJ. Botulinum toxin type B treatment in multiple sclerosis patients with lower-extremity adductor spasticity: results of a double-blind, placebo-controlled, safety study. Arch Phys Med Rehabil. 2007;88:E84
  14. Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007;21:331–337
  15. Jost WH. Botulinum toxin in multiple sclerosis. J Neurol. 2006;253(Suppl. 1):I16–20
  16. Royal College of Physicians . British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology/Spasticity in adults: management using botulinum toxin. National guidelines. London: RCP; 2009;pp. 40–7
  17. Wissel J, Entner T. Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis. Wien Klin Wochenschr. 2001;113(Suppl. 4):20–24
  18. Lamotte D, Thoumie P. Multiple sclerosis and botulinum toxin. Ann Readapt Med Phys. 2003;46:299–302
  19. Karsenty G, Reitz A, Wefer B, Boy S, Schurch B. Understanding detrusor sphincter dyssynergia – significance of chronology. Urology. 2005;66:763–768
  20. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–178
  21. Weld KJ, Graney MJ, Dmochowski RR. Clinical significance of detrusor sphincter dyssynergia type in patients with post-traumatic spinal cord injury. Urology. 2000;56:565–568
  22. Barbalias GA, Nikiforidis G, Liatsikos EN. Vesicourethral dysfunction associated with multiple sclerosis: clinical and urodynamic perspectives. J Urol. 1998;160:106–111
  23. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990;71:24–26
  24. Gallien P, Reymann JM, Amarenco G, Nicolas B, de Sèze M, Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76:1670–1676
  25. Schulte-Baukloh H, Schobert J, Stolze T, Stürzebecher B, Weiss C, Knispel HH. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn. 2006;25:110–115
  26. Kalsi V, Gonzales G, Popat R, Apostolidis A, Elneil S, Dasgupta P, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007;62:452–457
  27. Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo controlled, double-blind study. Scand J Urol Nephrol. 2007;41:335–340
  28. Lekka E, Lee LK. Successful treatment with intradetrusor Botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. Eur Urol. 2006;50:806–809
  29. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003;7(40):iii, ix–x, 1–111
  30. Jabbari B. Botulinum neurotoxins in the treatment of refractory pain. Nat Clin Pract Neurol. 2008;4:676–685
  31. Zadro I, Barun B, Habek M, Brinar VV. Isolated cranial nerve palsies in multiple sclerosis. Clin Neurol Neurosurg. 2008;110:886–888
  32. Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996;11:250–256
  33. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523–1528
  34. Pahwa R, Busenbark K, Swanson-Hyland EF, Dubinsky RM, Hubble JP, Gray C, et al. Botulinum toxin treatment of essential head tremor. Neurology. 1995;45:822–824
  35. Sedano MJ, Trejo JM, Macarrón JL, Polo JM, Berciano J, Calleja J. Continuous facial myokymia in multiple sclerosis: treatment with botulinum toxin. Eur Neurol. 2000;43:137–140
  36. Murthy R, Dawson E, Khan S, Adams GG, Lee J. Botulinum toxin in the management of internuclear ophthalmoplegia. J AAPOS. 2007;11:456–459
  37. Repka MX, Savine PJ, Rienechke RD. Treatment of acquired nystagmus with botulinum neurotoxin A. Arch Ophthalmol. 1994;112:1320–1324
  38. Ruben ST, Lee JP, O’Neil D, Dunlop I, Elston JS. The use of botulinum toxin for treatment of acquired nystagmus and oscillopsia. Ophthalmology. 1994;101:783–787
  39. Lennerstrand G, Nordbø OA, Tian S, Eriksson-Derouet B, Ali T. Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications. Acta Ophthalmol Scand. 1998;76:27–37
  40. Curé JK, Cromwell LD, Case JL, Johnson GD, Musiek FE. Auditory dysfunction caused by multiple sclerosis: detection with MR imaging. AJNR Am J Neuroradiol. 1990;11:817–820
  41. Stidham KR, Solomon PH, Roberson JB. Evaluation of botulinum toxin A in treatment of tinnitus. Otolaryngol Head Neck Surg. 2005;132:883–889
  42. Cruccu G, Biasiotta A, Di Rezze S, Fiorelli M, Galeotti F, Innocenti P, et al. Trigeminal neuralgia and pain related to multiple sclerosis. Pain. 2009;43:186–191
  43. Piovesan EJ, Teive HG, Kowacs PA, Della Coletta MV, Werneck LC, Silberstein SD. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology. 2005;65:306–308
  44. Raghav S, Kipp D, Watson J, Spring W. Gastroparesis with multiple sclerosis. Mult Scler. 2006;12:243–244
  45. Arts J, Holvoet L, Caenepeel P, Bisschops R, Sifrim D, Verbeke K, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26:1251–1258
  46. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103:416–423
  47. Irani K, Rodriguez L, Doody DP, Goldstein AM. Botulinum toxin for the treatment of chronic constipation in children with internal anal sphincter dysfunction. Pediatr Surg Int. 2008;24:779–783
  48. Varghese-Kroll E, Elovic EP. Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of poststroke spasticity. Am J Phys Med Rehabil. 2009;88(June (6)):495–499
  49. Bhatia KP, Münchau A, Thompson PD, Houser M, Chauhan VS, Hutchinson M, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry. 1999;67:90–93
  50. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77:918–926
  51. Esquenazi A. Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. Eur J Neurol. 2006;13(December (Suppl. 4)):27–34

PII: S0303-8467(10)00112-5

doi: 10.1016/j.clineuro.2010.04.010

Clinical Neurology and Neurosurgery
Volume 112, Issue 7 , Pages 592-596 , September 2010

Article Tools